LIXTE Biotech Remains Pre-Revenue, Faces Funding Hurdles

TL;DR

**LIXTE is a high-risk, pre-revenue biotech; only invest if you're betting on a long-shot drug breakthrough.**

AI Summary

LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported no revenue for the three and six months ended June 30, 2025, consistent with its pre-revenue stage as a pharmaceutical preparations company. The net loss for the three months ended June 30, 2025, was not explicitly stated but can be inferred from the lack of revenue and ongoing operational expenses typical of a biotech firm. For the six months ended June 30, 2025, the company also reported no revenue. Key business changes include continued focus on research and development, as indicated by the nature of a pharmaceutical company, though specific R&D expenditures were not detailed in the provided snippet. The company's strategic outlook remains centered on advancing its drug candidates, which inherently carries significant clinical trial and regulatory approval risks. Financial stability is a continuous risk, given the absence of revenue and reliance on external funding, as evidenced by the mention of common stock and warrants. The company's ability to secure future financing will be critical for its operations.

Why It Matters

For investors, LIXTE's continued pre-revenue status means its valuation is entirely speculative, tied to future drug development success rather than current financial performance. Employees face job security risks if funding falters, while potential customers (patients) are directly impacted by the pace and success of drug development. In the broader market, LIXTE operates in a highly competitive pharmaceutical landscape, where larger players with deeper pockets can outpace smaller biotechs. Its ability to innovate and secure partnerships is crucial for survival against industry giants.

Risk Assessment

Risk Level: high — The risk level is high because LIXTE BIOTECHNOLOGY HOLDINGS, INC. reported no revenue for the three and six months ended June 30, 2025, indicating a complete reliance on external financing for operations. The company's business model as a pharmaceutical preparations firm means substantial capital is required for R&D without guaranteed returns, making it highly speculative.

Analyst Insight

Investors should approach LIXT with extreme caution, recognizing it as a speculative bet on future drug development. Only those with a high-risk tolerance and a long-term investment horizon should consider a position, and even then, it should be a small portion of a diversified portfolio.

Financial Highlights

debt To Equity

Not Disclosed

revenue

$0

operating Margin

Not Disclosed

total Assets

Not Disclosed

total Debt

Not Disclosed

net Income

Not Disclosed

eps

Not Disclosed

gross Margin

Not Disclosed

cash Position

Not Disclosed

revenue Growth

N/A

Revenue Breakdown

Key Numbers

• $0 — Revenue for Q2 2025 (Indicates pre-revenue stage, consistent with prior periods.)
• $0 — Revenue for H1 2025 (Indicates pre-revenue stage for the first half of the year.)
• 0.0001 — Par Value Per Share (Par value of Common Stock and Warrants to Purchase Common Stock.)

Key Players & Entities

• LIXTE BIOTECHNOLOGY HOLDINGS, INC. (company) — filer of the 10-Q
• 0001335105 (regulator) — Central Index Key (CIK) for LIXTE
• 2025-06-30 (date) — Conformed Period of Report
• 2025-08-07 (date) — Filed As Of Date
• Pharmaceutical Preparations (company) — Standard Industrial Classification (SIC) for LIXTE
• Common Stock (dollar_amount) — type of equity mentioned in the filing
• Warrants (dollar_amount) — type of equity mentioned in the filing
• Series A Convertible Preferred Stock (dollar_amount) — type of equity mentioned in the filing

FAQ

Risk Factors

• Reliance on External Financing [high — financial]: As a pre-revenue biotechnology company, LIXTE BIOTECHNOLOGY HOLDINGS, INC. relies heavily on external funding to sustain its operations and advance its drug candidates. The absence of revenue generation creates a continuous risk of financial instability. The company's ability to secure future financing through common stock offerings, warrants, or other means is critical for its survival and progress.
• Drug Development and Approval Risks [high — regulatory]: The company's strategic focus on advancing drug candidates inherently involves significant risks associated with clinical trials and regulatory approval processes. Delays, failures in trials, or rejections by regulatory bodies can severely impact the company's future prospects and financial viability.
• Research and Development Execution [medium — operational]: Continued focus on research and development is central to LIXTE BIOTECHNOLOGY HOLDINGS, INC.'s business model. The success of its R&D efforts in developing viable drug candidates is paramount. Any setbacks or inefficiencies in R&D execution could lead to significant financial losses and delays in product development.
• Biotechnology Industry Volatility [medium — market]: The biotechnology sector is characterized by high volatility, driven by scientific breakthroughs, clinical trial outcomes, and regulatory changes. LIXTE BIOTECHNOLOGY HOLDINGS, INC. operates within this dynamic environment, making it susceptible to market fluctuations and investor sentiment shifts.

Industry Context

LIXTE BIOTECHNOLOGY HOLDINGS, INC. operates in the pharmaceutical preparations sector, a highly competitive and innovation-driven industry. The sector is characterized by long development cycles, significant R&D investment, and stringent regulatory oversight. Success hinges on the ability to discover, develop, and gain approval for novel therapeutic agents.

Regulatory Implications

As a biotechnology company, LIXTE BIOTECHNOLOGY HOLDINGS, INC. is subject to rigorous regulatory scrutiny from bodies like the FDA. The development and approval process for drug candidates is lengthy, costly, and uncertain, posing significant risks if trials fail or regulatory requirements are not met.

What Investors Should Do

1. Monitor financing activities closely.
2. Evaluate R&D pipeline progress.
3. Assess cash burn rate and runway.

Key Dates

• 2025-06-30: End of Second Quarter and First Half of Fiscal Year 2025 — Reporting period for the 10-Q filing, showing zero revenue and ongoing pre-revenue operations.
• 2025-08-07: Filing Date of the 10-Q Report — Indicates the company's financial and operational status as of June 30, 2025, and provides updated disclosures to investors.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance and condition. (This document provides the detailed financial information and disclosures for LIXTE BIOTECHNOLOGY HOLDINGS, INC. for the period ending June 30, 2025.)

Pre-revenue stage

A phase in a company's lifecycle where it has not yet generated any sales revenue, typically common for early-stage biotechnology or technology firms focused on research and development. (LIXTE BIOTECHNOLOGY HOLDINGS, INC. is in this stage, meaning its financial performance is characterized by expenses and losses rather than income.)

Par Value Per Share

The nominal value assigned to a security by the issuer, often a very small amount, such as $0.0001 for common stock and warrants. (Indicates the minimum legal capital required for the company's common stock and warrants, reflecting their basic share structure.)

Warrants to Purchase Common Stock

Financial instruments that give the holder the right, but not the obligation, to purchase a company's stock at a specified price within a certain timeframe. (These are a form of potential future dilution and a financing tool for the company, often issued alongside other securities.)

Year-Over-Year Comparison

The current 10-Q filing for the period ending June 30, 2025, shows no revenue, consistent with the company's pre-revenue stage, similar to prior periods. Specific financial metrics like net income, cash position, and margins are not detailed in the provided snippet, making a direct comparison of financial performance difficult. However, the ongoing reliance on external funding and the inherent risks of drug development remain key concerns, likely unchanged from the previous filing.

Key Financial Figures

• $0.0001 — ch registered Common Stock, par value $0.0001 per share LIXT The Nasdaq Stock Mar

Filing Documents

• form10q.htm (10-Q) — 1519KB
• ex10-3.htm (EX-10.3) — 476KB
• ex31-1.htm (EX-31.1) — 18KB
• ex31-2.htm (EX-31.2) — 19KB
• ex32-1.htm (EX-32.1) — 7KB
• ex32-2.htm (EX-32.2) — 7KB
• form10-q_001.jpg (GRAPHIC) — 117KB
• form10-q_002.jpg (GRAPHIC) — 53KB
• ex10-3_001.jpg (GRAPHIC) — 263KB
• ex10-3_002.jpg (GRAPHIC) — 304KB
• ex10-3_003.jpg (GRAPHIC) — 201KB
• ex10-3_004.jpg (GRAPHIC) — 71KB
• 0001641172-25-022517.txt ( ) — 9812KB
• lixt-20250630.xsd (EX-101.SCH) — 50KB
• lixt-20250630_cal.xml (EX-101.CAL) — 34KB
• lixt-20250630_def.xml (EX-101.DEF) — 276KB
• lixt-20250630_lab.xml (EX-101.LAB) — 442KB
• lixt-20250630_pre.xml (EX-101.PRE) — 353KB
• form10q_htm.xml (XML) — 1339KB

- FINANCIAL INFORMATION

PART I - FINANCIAL INFORMATION 3

Condensed Consolidated Financial Statements

Item 1. Condensed Consolidated Financial Statements 3 Condensed Consolidated Balance Sheets – June 30, 2025 (Unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations (Unaudited) – Three Months and Six Months Ended June 30, 2025 and 2024 4 Condensed Consolidated Statements of Stockholders' Equity (Unaudited) – Three Months and Six Months Ended June 30, 2025 and 2024 5 Condensed Consolidated Statements of Cash Flows (Unaudited) – Six Months Ended June 30, 2025 and 2024 7 Notes to Condensed Consolidated Financial Statements (Unaudited) – Three Months and Six Months Ended June 30, 2025 and 2024 8

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 43

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 65

Controls and Procedures

Item 4. Controls and Procedures 65

- OTHER INFORMATION

PART II - OTHER INFORMATION 66

Legal Proceedings

Item 1. Legal Proceedings 66

Risk Factors

Item 1A. Risk Factors 66

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 66

Defaults Upon Senior Securities

Item 3. Defaults Upon Senior Securities 66

Mine Safety Disclosures

Item 4. Mine Safety Disclosures 66

Other Information

Item 5. Other Information 66

Exhibits

Item 6. Exhibits 67

SIGNATURES

SIGNATURES 68 2 PART I - FINANCIAL INFORMATION ITEM 1. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS LIXTE BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED BALANCE SHEETS June 30, 2025 December 31, 2024 (Unaudited) ASSETS Current assets: Cash $ 887,212 $ 1,038,952 Prepaid insurance 14,597 20,898 Other prepaid expenses 87,943 85,653 Total current assets 989,752 1,145,503 Deferred offering costs 198,826 — Total assets $ 1,188,578 $ 1,145,503 LIABILITIES AND STOCKHOLDERS' EQUITY Current liabilities: Accounts payable and accrued expenses, including $ 10,000 and $ 27,500 to related parties at June 30, 2025 and December 31, 2024, respectively $ 92,149 $ 83,206 Research and development contract liabilities 256,147 235,078 Accrued offering costs 188,826 — Total current liabilities 537,122 318,284 Commitments and contingencies - - Stockholders' equity: Preferred Stock, $ 0.0001 par value; authorized – 10,000,000 shares; issued and outstanding – 0 350,000 shares of Series A Convertible Preferred Stock, $ 10.00 per share stated value, convertible into 0 72,917 shares of common stock — 3,500,000 Common stock, $ 0.0001 par value; authorized – 100,000,000 shares; issued and outstanding – 2,756,991 shares and 2,249,290 shares at June 30, 2025 and December 31, 2024, respectively 276 225 Additional paid-in capital 54,204,101 49,394,687 Accumulated deficit ( 53,552,921 ) ( 52,067,693 ) Total stockholders' equity 651,456 827,219 Total liabilities and stockholders' equity $ 1,188,578 $ 1,145,503 See accompanying notes to condensed consolidated financial statements. 3 LIXTE BIOTECHNOLOGY HOLDINGS, INC. AND SUBSIDIARY CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited) 2025 2024 2025 2024 Three Months Ended Six Months Ended June 30, June 30, 2025 2024 2025 2024 Revenues $ — $ — $ — $ — Costs and expenses: Research and dev

Business

Business The Company is a clinical-stage biopharmaceutical company focused on identifying new targets for cancer drug development and developing and commercializing cancer therapies. The Company's corporate office is located in Pasadena, California. The Company's product pipeline is primarily focused on inhibitors of Protein Phosphatase 2A, which is used to enhance cytotoxic agents, radiation, immune checkpoint blockers and other cancer therapies. The Company believes that inhibitors of protein phosphatases have significant therapeutic potential for a broad range of cancers. The Company is focusing on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100. The Company's activities are subject to significant risks and uncertainties, including the need for additional capital. The Company has not yet commenced any revenue-generating operations, does not have positive cash flows from operations, relies on stock-based compensation for a substantial portion of employee and consultant compensation, and is dependent on periodic infusions of equity capital to fund its operating requirements. Nasdaq Compliance The Company's common stock and public warrants are traded on the Nasdaq Capital Market under the symbols "LIXT" and "LIXTW", respectively. On June 2, 2023, the Company effected a 1-for-10 reverse split of its outstanding shares of common stock in order to remain in compliance with the $ 1.00 minimum closing bid price requirement of the Nasdaq Stock Market LLC ("Nasdaq"). On August 19, 2024, the Company received a letter from the Listing Qualifications Department (the "Staff") of Nasdaq indicating that the Company was not in compliance with the minimum stockholders' equity requirement of $ 2,500,000 for continued listing on the Nasdaq Capital Market under Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). 8 On October 3, 2024, the Company submitted a plan to the Staff to regain compliance with the Stoc

View Full Filing

View this 10-Q filing on SEC EDGAR